Free Trial

Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals logo
$4.94 +0.16 (+3.35%)
Closing price 04:00 PM Eastern
Extended Trading
$5.01 +0.07 (+1.42%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RXRX vs. BBIO, VRNA, ELAN, BPMC, ROIV, GRFS, LEGN, RVMD, RYTM, and RNA

Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Grifols (GRFS), Legend Biotech (LEGN), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

Recursion Pharmaceuticals vs. Its Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Recursion Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 41.70%. BridgeBio Pharma has a consensus target price of $61.35, indicating a potential upside of 25.01%. Given Recursion Pharmaceuticals' higher possible upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than BridgeBio Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
BridgeBio Pharma
0 Sell rating(s)
0 Hold rating(s)
17 Buy rating(s)
0 Strong Buy rating(s)
3.00

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BridgeBio Pharma has a net margin of -329.25% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. BridgeBio Pharma's return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-1,004.91% -76.09% -54.29%
BridgeBio Pharma -329.25%N/A -85.69%

Recursion Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

In the previous week, BridgeBio Pharma had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 15 mentions for BridgeBio Pharma and 14 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.78 beat BridgeBio Pharma's score of 0.72 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
7 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
BridgeBio Pharma
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Recursion Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$58.84M36.45-$463.66M-$1.78-2.78
BridgeBio Pharma$221.90M42.28-$535.76M-$4.09-12.00

Summary

BridgeBio Pharma beats Recursion Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXRX vs. The Competition

MetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$2.08B$2.80B$5.82B$9.73B
Dividend YieldN/A1.66%3.84%4.09%
P/E RatioN/A22.6131.1525.97
Price / Sales36.45751.84476.16171.70
Price / CashN/A173.2237.1558.38
Price / Book2.335.869.116.39
Net Income-$463.66M$31.83M$3.26B$265.66M
7 Day Performance-14.38%1.80%2.11%1.98%
1 Month Performance-24.46%4.36%5.12%1.33%
1 Year Performance-32.79%11.44%31.25%21.15%

Recursion Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXRX
Recursion Pharmaceuticals
2.6387 of 5 stars
$4.94
+3.3%
$7.00
+41.7%
-37.3%$2.08B$58.84M-2.78400Positive News
Insider Trade
BBIO
BridgeBio Pharma
4.6819 of 5 stars
$49.66
-3.2%
$61.35
+23.5%
+96.5%$9.50B$221.90M-12.14400Insider Trade
VRNA
Verona Pharma PLC American Depositary Share
2.4702 of 5 stars
$105.74
+0.4%
$109.00
+3.1%
+276.7%$9.00B$42.28M-106.8030Positive News
Short Interest ↓
ELAN
Elanco Animal Health
2.9834 of 5 stars
$17.76
-1.1%
$17.33
-2.4%
+17.8%$8.82B$4.44B20.659,000Analyst Downgrade
BPMC
Blueprint Medicines
0.5063 of 5 stars
$129.46
flat
$130.00
+0.4%
N/A$8.36B$562.12M-52.41640
ROIV
Roivant Sciences
3.4873 of 5 stars
$11.83
-0.2%
$16.50
+39.5%
+0.2%$8.04B$29.05M-16.89860
GRFS
Grifols
3.721 of 5 stars
$10.60
-1.2%
$10.30
-2.8%
+31.4%$7.28B$7.81B9.0623,822Short Interest ↑
LEGN
Legend Biotech
3.8195 of 5 stars
$37.62
+0.3%
$72.38
+92.4%
-37.1%$6.91B$627.24M-42.722,609
RVMD
Revolution Medicines
4.4203 of 5 stars
$36.56
+0.7%
$69.54
+90.2%
-19.4%$6.83B$11.58M-8.12250Positive News
Analyst Revision
RYTM
Rhythm Pharmaceuticals
3.8106 of 5 stars
$97.40
-0.2%
$101.57
+4.3%
+124.1%$6.47B$130.13M-32.36140News Coverage
Positive News
RNA
Avidity Biosciences
3.2165 of 5 stars
$44.81
-3.6%
$67.00
+49.5%
-0.8%$5.76B$10.73M-12.57190Positive News
Insider Trade
Options Volume

Related Companies and Tools


This page (NASDAQ:RXRX) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners